Tuesday, July 21, 2026

Cadaver Fat for Cosmetic Enhancement

The question: Is the use of "harvested" human fat allowed al pi halacha for cosmetic procedures.  (We are talking about adipose tissue that has had the DNA scrubbed, leaving only the basic chemicals and the scaffolding. In this discussion we are going to call it 'fat.')

Not all poskim allow any invasive procedure for cosmetic purposes, including cosmetic surgery. Here, we are going to follow those who are mattir.

There are three kinds of fat implants: 

a. Autologous transfer, where fat is transferred from one part of the body to another. 

b. Heterologous transfer from a living person, where fat is taken from one person and transferred to another. For example, A is having fat reduction surgery and he allows the tissue to be used for such purposes.

c. Heterologous transfer from a cadaver.


Discussion.

a and b: Human body parts taken from a living person are not assur b'hana'ah.  But is there an obligation to bury them? 

Reb Moshe (אגרות יו'ד רל'א-ב) discusses whether flesh removed from a living person requires burial. He brings the Noda BeYehuda who says there is no such requirement. He says that while he disagrees with the Noda Be'Yehuda to the extent that he requires burial so that it should not be left in disgrace. If it is being used for an important purpose, he says there is nothing wrong with using בשר מן החי.  I assume that this reasoning is necessary to be mattir blood transfusions as well.

c: Fat taken from cadavers used for cosmetic procedures.  (The basic question can be asked about bone used for bone grafts, and cornea transplants. But as we will see, there is a difference in halacha between what can be done in case of medical need and what can be done for cosmetics.)   

Here's the article I read about it.


GLP-1s are shrinking bodies. Cadaver fat is plugging the gap

By  Leah Dolan

Jul 13, 2026

A buzzy new body contouring injectable is being made from donated cadaver fat. Doctors "haven't had to really explain it much." 


Sandra*, a 43-year-old media lawyer based in Los Angeles, had been toying with the idea of breast augmentation since her 20s, but was always put off by the pain of the procedure, the long recovery time and the idea of having “this kind of foreign sac in your body.”

So when Sandra, who wanted to protect her identity for privacy reasons, heard about a new injectable body contouring product last summer, she was intrigued. No synthetic fillers, no implanted sacs, no downtime.

“You hit a certain age and you decide, I’m going to do something for myself at this point,” she said. The product she found — alloClae, pronounced allo-clay like the earthy sculpting material — is quick to administer. Nicknamed the lunchtime boob-job, it often takes less than an hour to inject and doesn’t need general anaesthesia or a hospital setting. Plus, the aftercare instructions, Sandra said, were “shockingly easy.” The fact that alloClae uses fat harvested from donated dead bodies, or cadavers as they’re referred to in the scientific community, didn’t really pose an issue. “I was fine with that,” she said.

A growing number of people in the US appear to feel the same. Tiger Aesthetics, the company that manufactures alloClae, said more than 2,000 patients have been injected with it since May 2025. It’s a buzzy topic on Reddit’s popular plastic surgery page, as potential patients ask questions, seek reviews and swap doctor recommendations.

In 2026, it’s clear that what once might have been classed as body modification is now seen simply as body maintenance. It has never been easier, or more mundane, to drastically alter one’s physical form. Rib remodeling. Upper blepharoplasty. Lower blepharoplasty. Mid-facelift. Lower facelift. Deep-plane facelift. As science and surgical technique progress ad nauseam, so does our appetite for new curves, tighter skin, sharper jawlines.

AlloClae — one of the more inventive products in this category— is our latest reminder. But for every plastic surgery clinic calling the injectable a “next-generation” advancement, there’s an equal number of headlines branding it “zombie filler” or “corpse injections.”

If there is a boundary line in the pursuit of the perfect look, are we finally butting up against it? What does it mean if society widely embraces injecting cadaver fat in the service of beauty? Could alloClae become as common as Botox?

In the end, your opinion of alloClae might depend on your opinion of death.

The Ozempic effect

AlloClae was first released in the US in 2024 to board-certified plastic surgeons with a track record of working with fat, and since January to a wider net of doctors including “mid-level providers” like physicians assistants, nurse practitioners and aesthetic nurses. (Tiger Aesthetics said it trains nurse practitioners, who are not permitted to inject into the breast, on special injection technique.)

Dr. Luis Macias, a double-board-certified plastic surgeon in LA who was one of a select few doctors to receive alloClae early, has witnessed the product’s rising popularity first-hand. “I have to buy a lot of syringes at a time, and talk to the rep constantly about it,” he said in a phone interview. “I feel like I’m talking to my Porsche dealer… It’s ridiculous.” The price for one 12.5cc syringe of the soft tissue corrector can run up to roughly $2,250.

Marketed as “off-the-shelf” fat, or “bottled fat grafting,” as one PR email put it, alloClae is touted as an alternative to autologous fat grafting — where a patient’s own fat is removed via liposuction and transferred into another area.

It isn’t the first product in this area of cosmetics. Renuva, a similar shelf-stable cadaver fat injectable made by not-for-profit organization MTF Biologics, first launched around a decade ago. The key difference between the two, Macias said, is volume. Because Renuva’s maximum syringe size is just 3ccs, it was commonly used in smaller areas like the hands, face and neck, whereas the largest syringe of alloClae can hold around 22cc of more product. “It’s a little chunkier,” said Macias. “A little firmer.”

In the age of GLP-1s where bodies seem to be shrinking left and right, donated cadaver fat is plugging an emerging gap in the market. Around 11% of Americans are currently on medications such as Ozempic and Wegovy for weight loss, according to a report published this month. Macias says a number of his patients on GLP-1s are keen to add fat back into their bodies, now that they can spot treat areas and design their silhouette. “They want it back in the breast and buttocks, in the face,” he said. “Those are very common areas that we’re re-volumizing after we get rid of the excess skin.”

Caroline Van Hove, president of Tiger Aesthetics, agreed the rise in these drugs has been “complementary” to alloClae. “What these patients are finding is that as they’ve lost quite substantial amounts of weight, it’s also left them disfigured in certain areas where they have lost real targeted volume,” she said over Zoom. “In areas that, in their opinion, define their femininity.”

To meet the booming demand, Van Hove said the company is scaling up production, which might sound difficult for a company that relies entirely on the donation of dead bodies. Macias says he’s yet to see a patient bat an eyelid at where the fat comes from. “Maybe it’s because of the market I’m in,” he said. “Los Angeles, right?”

Cadaver ethics

Do families, and donors, know their bodies can be used in this way? The short answer is not always.

Organ and whole body donation are often understood as the ultimate selfless acts — a grieving family using their loss to improve someone else’s life, or further scientific research.

Organ donation is relatively straightforward — in the US it is tightly controlled by federal law. But whole body donation and non-transplant human tissue banks are a different story. Regulation varies by state and there is currently no mandatory federal accreditation or licensing requirement for either body donation organizations or non-transplant tissue banks, which are not regulated by the US Food and Drug Administration. This means there is largely no federal oversight of the hundreds of facilities receiving tens of thousands of gifted dead bodies per year.

Still, Van Hove called whole body donation a “stringent and highly regulated area.” She said Tiger Aesthetics only has contracts with tissue banks connected with the Association for Advancing Tissue and Biologics — a voluntary accrediting body established in 1976 with the aim of increasing public trust by providing additional scrutiny to the donation process. Donors “have to complete a very extensive dossier releasing their consents,” Van Hove said, adding that it can take between 3 and 6 months to “clear” a donor’s medical record and approve the anatomical gift. “Obviously the form does not say ‘Do you want to donate your organs or tissue to alloClae?’” she said. “But it allows the donor to really indicate whether or not they want it exclusively for investigative research, medical research or if they’re also allowing for-profit purposes and so on, or if they have no restrictions at all.”

AlloClae is particularly popular with GLP-1 users, who want to add fat back into specific areas after weight loss.

AlloClae is particularly popular with GLP-1 users, who want to add fat back into specific areas after weight loss. Photo Illustration by Connie Chen/CNN

Whether it’s ethical is another question, especially since families of donors are not compensated for their loved one’s body. “It really is betraying altruism to make money,” Arthur Caplan, professor of bioethics at NYU’s Grossman School of Medicine, said of the industry more generally in a video call. “I think that’s an ethics problem.”

In terms of increasing production, Tiger Aesthetics told CNN they are partnering with more tissue banks across the US to access extra cadavers and plan to widen the age criteria for eligible donors. But its efforts to scale were somewhat disrupted this summer when the New York State Health Department denied the product’s distribution. New York is one of the few states in the country which require non-transplant tissue banks and those distributing, processing, storing or collecting human tissue to hold a license. According to recent court filings, the Department of Health rejected a license for alloClae manufacturers in October 2024 on the grounds that it was “unclear” whether the injectable was “in compliance with FDA requirements” and again in May 2026 because “the tissue bank owners, controlling parties, medical director or tissue bank director do not have the character and competence to ensure that the facility is competently operated in accordance with the law.” Tiger, who insists its product is “lawfully regulated” by the FDA, has filed a lawsuit against the Department of Health which it believes does not have the authority to block the product. The company is seeking damages of at least $500,000 for lost revenue and a declaration from the court that the “New York Tissue Bank regulatory scheme does not apply to adipose tissue-derived products” like alloClae, among other relief.

‘Oily, chunky and yellow’

When asked about the question of donated cadaver fat, Jackelin Cruz, a patient of Macias, said she initially found it “a little bit weird.” But she was comforted by the fact that, according to Tiger Aesthetics, the donor’s DNA is removed in the manufacturing process.

Cruz, a 60-year-old stay-at-home mom living in LA was waiting in Macias’ clinic for her usual Botox and lasers appointment when she saw a pamphlet for alloClae. She had already thought about adding volume to her buttocks — sometimes, she felt shy even walking in front of her husband and preferred to tie a sweater around her waist — but Macias told her she was too lean for a traditional Brazilian butt lift, also known as a BBL. Even if she had enough fat reserves, Cruz didn’t like the sound of the surgery’s recovery. Instead, she was “sold” on alloClae’s minimal downtime, and the idea that her desired shape could be built up slowly with the injectable over a few sessions. In the end, she had two rounds costing just under $50,000 altogether. She loved the result of her alloClae treatment so much, she’s considering using it in other areas of her body.

Sandra, meanwhile, spent $13,000 for 50cc of alloClae in each breast. She thought it was a good deal, thanks to a volume discount from her surgeon. But she ended up facing complications. Around two months after her breast augmentation, Sandra said her right side became painful, and the skin was turning yellow-brown and purple like a bruise. She said she could feel lumps in her breast, and was eventually told by her surgeon she had something called fat necrosis. The injected fat wasn’t able to vascularize — the process where new blood vessels form and increase blood supply to the area — and was now dying inside her body. One time after showering, Sandra said she noticed yellow fluid seeping out of the injection site of her right breast. “It very much looked like the alloClae,” she said. “It looked oily, chunky and yellow.”

According to Van Hove, Tiger Aesthetics does not have any confirmed cases of graft rejection or infection of alloClae. She said she could not comment on the details of Sandra’s experience, which would have been handled by the company’s quality assurance team, but added that injecting “technique is very important.”

Both Van Hove and Dr. Krishna Vyas, a plastic surgeon based in New York, said that standard fat grafting with your own biology also poses a risk of necrosis, though any further evaluation is difficult since there are currently no direct comparison studies between the two techniques. While Vyas noted that the product seemed “low risk,” he is hesitant to use it in his own practice before more robust clinical trials with long term follow-up data are published.

Sandra’s cysts were successfully aspirated, but she said she can still feel some lumps in her chest and was, ironically, told she may need surgery to remove any remaining alloClae.

Caroline Van Hove, president of alloClae's manufacturer Tiger Aesthetics, is behind some of the most recognisable injectables on the market. Her career includes PR for Botox and Juvéderm, two products that have been re-shaping faces for decades.

Caroline Van Hove, president of alloClae's manufacturer Tiger Aesthetics, is behind some of the most recognisable injectables on the market. Her career includes PR for Botox and Juvéderm, two products that have been re-shaping faces for decades. Photo Illustration by Connie Chen/CNN/berkpixels/fStop/Getty Images

The new Botox?

When he first began working with Renuva and alloClae, Macias steeled himself against what he expected would be widespread horror at the idea of “putting dead people’s fat into people.”

“For some reason,” he said. “I haven’t had to really explain it that much.”

Arabelle Sicardi, a cultural critic and author of “The House of Beauty: Lessons from the Image Industry,” called alloClae “horrifically convenient,” likening it to something in the universe of Coralie Fargeat’s 2024 body horror film, “The Substance.”

Sicardi thought the lack of downtime or recovery added to a kind of cognitive dissonance regarding the product’s ingredient list. “It says that we’re prioritizing convenience with materials of the dead,” Sicardi said. “This is just a new version of an ancient impulse. People used to eat dead bodies. Now we’re shooting them into our bodies.”

But Van Hove is confident about the injectable’s future success. And she has reason to be, having held a career at the forefront of the medical aesthetics industry for decades. She has helped to launch two of the most recognizable products in the cosmetics world: Botox and Juvéderm. Fillers, Botox, lasers, needling, “all those things at one point or another were considered extreme because they were new,” Van Hove said. “I think all of those products should be considered as they’re helping mental well-being and self-confidence.”

Rather than representing human expiration, she sees alloClae as a sort of cosmetic lifeblood. “People are also looking for ways to not only live longer and live better, but also to look and feel their very best as they’re extending their own life span,” Van Hove said.

“Why do everything possible to live a longer life when you feel that the outside doesn’t really project the inner youth that you’ve strived for.”


Halacha.

1. A human corpse is assur b'hana'ah. This might not apply to hair and skin, but it certainly applies to fat.

עבודה זרה כ"ט:  

ומת גופיה מנלן אתיא שם שם מעגלה ערופה כתיב הכא {במדבר כ-א} ותמת שם מרים וכתיב התם {דברים כא-ד} וערפו שם את העגלה בנחל מה להלן אסור בהנאה אף כאן נמי אסור בהנאה והתם מנלן אמרי דבי רבי ינאי כפרה כתיב בה כקדשים:

2. Hana'ah from a meis is an issur deoraysa. There is a machlokes Rishonim and Achronim whether this issur is deoraysa applies to everyone, or only to Jews- If a non-Jew wishes to donate his body, the Torah allows him to do so. Even so, everyone agrees that there is at least an issure derabanan, that the Rabanan prohibited us from using it, even if he donated it willingly. 

שו"ע יו"ד שמט, א
איסור הנאה במת ובתכריכיו. ובו ד' סעיפים:
מת בין עובד כוכבים בין ישראל תכריכיו אסורים בהנאה ודוקא שהזמינם לצרכו ונתנם עליו אבל בהזמנה לבד אפילו עשאם לצרכו לאחר שמת לא נאסרו דהזמנה לאו מלתא וכן אם נתנם עליו ולא הזמינם לכך בתחילה עדיין לא נאסרו:
פתחי תשובה
בין עובד כוכבים. עבה"ט של הרב מהרי"ט ז"ל ועי' בתשו' אבן שהם סי' ל' שהעלה דמת ישראל אסור בהנאה מה"ת אבל מת עובד כוכבים אסור מדרבנן ומה"ט כתב שם באחד שחלה חולי שאב"ס ואמרו הרופאים שיקח עצם ממת לצורך איזה רפואה או מתכריכי המת דמותר ליקח עצם עובד כוכבים לזה כיון שאינו אלא מדרבנן ע"ש. ועיין עוד בתשו' צמח צדק סי' י"ג ובהג"ה שם. ובתשו' יד אליהו סי' ס"ו ובתשו' פרי תבואה סי' כ"ה ובספר ברכי יוסף להגאון מהר"ר חיד"א ז"ל ובשאילת יעב"ץ ח"א סי' מ"א ובשו"ת תשובה מאהבה ח"א סי' מ"ז ובתשו' הרב הגדול מהר"ר ברוך בעל טעם המלך:


And here is the Mishneh LeMelech Eivel 14:21

שוב זיכני ה' וראיתי שדין זה מבואר בירושלמי דשבת עלה דמתני' דכזית מן המת דקא אמרי בפירוש דבשר עכו"ם מת מותר בהנאה. ואף שדברי הירושלמי שם הם צריכין ביאור מ"מ כל הישר הולך יראה בעיניו ולבבו יבין דלפי פשט הירושלמי עכו"ם מותר בהנאה וליראת האריכות לא הארכתי בביאור דברי הירושלמי. ולפי זה אני תמיה על הרשב"א והריטב"א והרא"ה שכתבנו למעלה משמם דס"ל דבשר העכו"ם אסור בהנאה איך לא השגיחו בדברי הירושלמי הללו:     

3. If the issur is derabanan for non=Jews, then at least for Ashkenazim the Rama allows using it for refuah even when there is no sakana, even for a חולה שאין בו סכנה.

יו'ד קנ'ה ג

בשאר איסורים מתרפאים במקום סכנה אפי' דרך הנאתן ושלא במקום סכנה כדרך הנאתן אסור יגשלא כדרך הנאתן מותר חוץ מכלאי הכרם ובשר בחלב שאסורים אפילו שלא כדרך הנאתן אלא במקום סכנה: הגה ועיין לעיל סימן קכ"ג י"א דכל איסורי הנאה מדרבנן מותר להתרפאות בהן טואפילו חולה שאין בו סכנה (ר"ן פכ"ש בשם י"א וריב"ש סי' מ"ה) ואפי' יין נסך טזבזמן הזה מותר להתרפאות בו יזולעשות ממנו מרחץ אע"פ שהוא כדרך הנאתן ובלבד שלא יאכל וישתה האיסור הואיל ואין בו סכנה וכל שכן יחדמותר לזלף יין על גבי אש דאפי' לבריא מותר דריחא לאו מילתא היא (ארוך כלל ל "ט) 

4. Reb Shlomo Kluger   האלף לך שלמה יו'ד רב  says that even by an issur deoraysa, חצי שיעור would be even more kal than a derabanan for a choleh. Now go figure out what Chatzi shiur is by organ  or tissue transplants.

5.  Also: Even if the issur is deoraysa, or in the case of a Jewish body, some (Reb Shlomo Zalman מנחת שלמה חלק ב סימן פד quoting Rav Unterman) say that because the tissue is biologically incorporated into a living person, it is no longer assur b'hana'ah, because it is no longer bassar hameis. This might not solve the obligation to bury the tissue.

So here is what I say from a halachic perspective. The use of cadaveric fat for cosmetic purposes is assur. The issur may be deoraysa, the issur may be derabanan, but assur it is. The application of Reb Shlomo Kluger's chatzi shiur and the Rama's hetter are useless where there is no medicinal need.

Here is what I say from an ethical perspective: The use of cadaveric fat for cosmetic purposes is a breath-takingly spectacular commodification of the human being, and is indistinguishable from using it for culinary purposes. 


NOTE: I don't think I would be dismayed by the idea of draining a cadaver's blood to use for transfusion, but that's because taking a live person's blood is not an assault on his bodily integrity.

Cadaveric blood can be and at one time was used for transfusion.


Speaking of commodification of the human body, I wish to point out that I do not believe that capital punishment treads on the same ground by any means. If anything, capital punishment emphasizes the importance of human life. 

I coincidentally saw the following opinion piece and letter in the WSJ on July 21 2026.

Can We Kill You for Your Organs, Please?

An academic paper raises a chilling new concern about assisted suicide.


In a recent New England Journal of Medicine article, three medical academics, two of whom are bioethicists, argue that the growing acceptance of voluntary euthanasia “warrants a recontextualization of the dead donor rule and assessment of the ethical principles involved.” Behind the obscurantist language is a horrifying proposal, which co-author Robert Truog described in an interview: Patients “would receive an anesthetic . . . and under anesthesia, the organs would be removed . . . while they’re still functioning.”
Assisted suicide raises enough ethical concerns as it is. The National Council on Disability, on which I served, noted in a 2019 report the longstanding concern that “if assisted suicide is legal, some people’s lives, particularly those of people with disabilities, will be ended without their fully informed and free consent, through mistakes, abuse, insufficient knowledge, and the unjust lack of better options.” Exploiting assisted suicide to increase the supply of donated organs would increase the likelihood that vulnerable patients will feel pressured to end their lives.

Apart from whether it violates state criminal statutes regarding euthanasia and murder, federal policy should forbid the ghoulish, macabre practice the authors call “death via organ donation” before it begins. The Trump administration should immediately issue guidance specifying that a 1997 law prohibiting federal funding of assisted suicide applies to any instances of death via organ donation. If Medicare, Medicaid and other federal insurance options and grant programs refuse to cover the costs of an organ transplant that is the product of assisted suicide, few hospitals will contemplate undertaking them.

In addition, the Department of Health and Human Services should direct the Organ Procurement and Transplantation Network to adopt a policy explicitly prohibiting death via organ donation. The OPTN’s policies carry great weight because Section 1138 of the Social Security Act provides that transplant hospitals may participate in Medicare and Medicaid “only if . . . the hospital is a member of, and abides by the rules and requirements of” the OPTN. With all Medicare and Medicaid payments contingent on compliance with OPTN policies, a single instance of death by organ donation would put a hospital’s existence in jeopardy.

Ultimately, Congress should amend the National Organ Transplant Act to prohibit organ donations caused by assisted suicide, just as it already prohibits the interstate sale of human organs. A recent bicameral letter calling for monitoring of hospice patients regarding so-called aid in dying illustrates bipartisan concern that vulnerable patients could be pressured into ending their lives. That suggests there could be broad bipartisan support for a prohibition on death via organ donation, as there was for the 1997 law on assisted suicide and the 2023 law reforming the organ transplant system.

As a mother of a child with cystic fibrosis, I recognize the anguish that patients in need of a life-saving organ transplant face. But we can do better than killing people—even people who claim they wish to die—to harvest their organs.

And this, a letter, also on 7/21.

The ICC in Inaction: Chinese Organ Harvesting
The body’s failure to address allegations that Beijing is using detainees in this way is one of the most glaring instances of its ineptitude.
I applaud Secretary of State Marco Rubio’s July 14 op-ed “Why We’re Dismantling the ICC.” Regardless of the issues involving the International Criminal Court outlined by Mr. Rubio, there is one glaring omission in its portfolio which he doesn’t mention: its failure to address the evidence that China is subjecting detainees from ethnic minority and faith groups to forced organ harvesting.

The independent China Tribunal has investigated charges of Chinese forced organ harvesting, and concluded in 2020 that the Chinese Communist Party had “beyond reasonable doubt” committed this crime. Beijing denied the tribunal’s findings.

The ICC lacks a jurisdictional path over conduct occurring entirely within China, unless the United Nations Security Council refers the situation to the ICC. Such a referral likely hasn’t happened because China is a permanent member of the Security Council with veto power.

Advocacy groups such as Doctors Against Forced Organ Harvesting, which I worked for the past two decades, have argued for years that the alleged forced organ harvesting could constitute crimes against humanity, but this hasn’t resulted in an ICC case or public investigation.

Mr. Rubio states that at its inception the ICC was proposed as a backstop against the gravest crimes. Most would agree that a country’s using its minorities as industrial merchandise for a booming transplant industry qualifies as a grave offense. Mr. Rubio is right, the ICC has outlived its usefulness—whatever that was.

Prof. Em. Lucia Dunn

Ohio State University

Columbus, Ohio

This will come to include the option of not only harvesting organs (optimally while the donor is still alive,) but also fat. Looking at the bright side, this will have the positive result of  improving the treatment of prisoners in China, à la Hansel and Gretel.

No comments:

Post a Comment